Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture

Abstract

The number of hip fractures in anticoagulated patients is predicted to increase, due to people living longer. However, evidence regarding urgent perioperative management of elderly patients with hip fracture who take oral anticoagulants (vitamin K antagonists or direct oral anticoagulants) is scarce. In this article, the authors present a narrative review of the evidence to date supporting the urgent management of hip fracture in anticoagulated elderly patients. They discuss the complexity of managing the high risk of procedure-related bleeding and, at the same time, the high risk of thromboembolism. The role of a bridging procedure and the best strategy of anticoagulation reversal are also reviewed. Further studies are required to improve the evidence in urgent surgery, especially in frail elderly patients.

Keywords

anticoagulants - hip fractures - venous thromboembolism - hemorrhage - aged - emergencies

Source of Support

No source of support was provided for this paper.

• References

• 1 Steinberg BA, Peterson ED, Kim S. , et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (05) 488-494
• 2 No authors cited. The National Hip Fracture Database. National Report, 2010. Available at: http://www.ccad.org.uk/nhfd.nsf/NHFD_National_Report_2010.pdf . Accessed August 3, 2016
• 3 White SM, Griffiths R, Holloway J, Shannon A. Anaesthesia for proximal femoral fracture in the UK: first report from the NHS Hip Fracture Anaesthesia Network. Anaesthesia 2010; 65 (03) 243-248
• 4 Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. ; IOF Working Group on Epidemiology and Quality of Life. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23 (09) 2239-2256
• 5 Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 2016; 14 (05) 875-885
• 6 Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 2010; 39 (02) 203-209
• 7 Folbert EC, Hegeman JH, Gierveld R. , et al. Complications during hospitalization and risk factors in elderly patients with hip fracture following integrated orthogeriatric treatment. Arch Orthop Trauma Surg 2017; 137 (04) 507-515
• 8 Smith T, Pelpola K, Ball M, Ong A, Myint PK. Pre-operative indicators for mortality following hip fracture surgery: a systematic review and meta-analysis. Age Ageing 2014; 43 (04) 464-471
• 9 American Academy of Orthopaedic Surgeons. Management of hip fracture in the elderly: evidence-based clinical practice guideline; 2014. Available at: www.aaos.org/Research/guidelines/HipFxGuideline.pdf . Accessed December 30, 2015
• 10 National Institute for Health and Care Excellence (NICE). Hip Fracture: The Management of Hip Fracture in Adults. CG124. London, UK: NICE; 2011
• 11 Falck-Ytter Y, Francis CW, Johanson NA. , et al. College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e278S-325S
• 12 Abelseth G, Buckley RE, Pineo GE, Hull R, Rose MS. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma 1996; 10 (04) 230-235
• 13 McMurtry MS, Cairns JA. Anticoagulation in elderly patients with chronic kidney disease: how safe is it?. Can J Cardiol 2016; 32 (08) 941.e3-941.e5
• 14 Harel Z, Mamdani M, Juurlink DN. , et al. Novel oral anticoagulants and the risk of major hemorrhage in elderly patients with chronic kidney disease: a nested case-control study. Can J Cardiol 2016; 32 (08) 986.e17-986.e22
• 15 Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev 2002; (04) CD000305
• 16 Fisher W. Managing hip fracture and lower limb surgery in the emergency setting: potential role of non-vitamin K antagonist oral anticoagulants. J Trauma Acute Care Surg 2017; 82 (06) 1112-1121
• 17 Lassen MR, Haas S, Kreutz R, Mantovani LG, Holberg G, Turpie AG. Rivaroxaban for thromboprophylaxis after fracture-related orthopedic surgery in routine clinical practice. Clin Appl Thromb Hemost 2016; 22 (02) 138-146
• 18 Fuji T, Fujita S, Kawai Y. , et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res 2014; 133 (06) 1016-1022
• 19 Long A, Zhang L, Zhang Y. , et al. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures. J Thromb Thrombolysis 2014; 38 (03) 299-305
• 20 Conteduca F, Massai F, Iorio R, Zanzotto E, Luzon D, Ferretti A. Blood loss in computer-assisted mobile bearing total knee arthroplasty. A comparison of computer-assisted surgery with a conventional technique. Int Orthop 2009; 33 (06) 1609-1613
• 21 Zhang P, He J, Fang Y, Chen P, Liang Y, Wang J. Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: a meta-analysis. Medicine (Baltimore) 2017; 96 (21) e6940
• 22 Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120 (15) 2954-2962
• 23 Venker BT, Ganti BR, Lin H, Lee ED, Nunley RM, Gage BF. Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis. J Arthroplasty 2017; 32 (02) 645-652
• 24 Riva N, Dentali F, Permunian ET, Ageno W. Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis. Semin Thromb Hemost 2016; 42 (01) 42-54
• 25 Sridharan K, Sivaramakrishnan G. Tranexamic acid in total knee arthroplasty: mixed treatment comparisons and recursive cumulative meta-analysis of randomized, controlled trials and cohort studies. Basic Clin Pharmacol Toxicol 2018; 122 (01) 111-119
• 26 Oktay E. Will NOACs become the new standard of care in anticoagulation therapy?. Int J Cardiovasc Acad 2015 DOI: 10.1016/j.ijcac.2015.06.007
• 27 Food and Drug Administration. FDA NEWS RELEASE. FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding. Available at: http://wayback.archive-it.org/7993/20170112213533/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350026.htm . Accessed April 29, 2013
• 28 European Medicines Agency. Core SPC for human prothrombin complex products [CPMP/BPWG/3735/02]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003518.pdf . Accessed January 12, 2012
• 29 Chai-Adisaksopha C, Hillis C, Siegal DM. , et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016; 116 (05) 879-890
• 30 Fariborz Farsad B, Golpira R, Najafi H. , et al. Comparison between prothrombin complex concentrate (PCC) and fresh frozen plasma (FFP) for the urgent reversal of warfarin in patients with mechanical heart valves in a tertiary care cardiac center. Iran J Pharm Res 2015; 14 (03) 877-885
• 31 Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99 (03) 251-260
• 32 Ortmann E, Besser MW, Sharples LD. , et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015; 121 (01) 26-33
• 33 Al-Rashid M, Parker MJ. Anticoagulation management in hip fracture patients on warfarin. Injury 2005; 36 (11) 1311-1315
• 34 Tharmarajah P, Pusey J, Keeling D, Willett K. Efficacy of warfarin reversal in orthopedic trauma surgery patients. J Orthop Trauma 2007; 21 (01) 26-30
• 35 Bhatia M, Talawadekar G, Parihar S, Smith A. An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture. Ann R Coll Surg Engl 2010; 92 (06) 473-476
• 36 Forster R, Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database Syst Rev 2016; 3: CD004179
• 37 Schulman S, Carrier M, Lee AY. , et al; Periop Dabigatran Study Group. Perioperative management of dabigatran: a prospective cohort study. Circulation 2015; 132 (03) 167-173
• 38 Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ. Minimizing the risk of bleeding with NOACs in the elderly. Drugs Aging 2016; 33 (07) 491-500
• 39 Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 2014; 14 (03) 175-189
• 40 Godier A, Dincq AS, Martin AC. , et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38 (31) 2431-2439
• 41 Pollack Jr CV, Reilly PA, van Ryn J. , et al. Idarucizumab for dabigatran reversal- full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
• 42 Connolly SJ, Milling Jr TJ, Eikelboom JW. , et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
• 43 Huisman MV, Fanikos J. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. Am J Emerg Med 2016; 34 (11S): 46-51
• 44 Flaker GC, Theriot P, Binder LG, Dobesh PP, Cuker A, Doherty JU. Management of periprocedural anticoagulation: a survey of contemporary practice. J Am Coll Cardiol 2016; 68 (02) 217-226
• 45 Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126 (13) 1630-1639
• 46 Douketis JD, Spyropoulos AC, Spencer FA. , et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e326S-e350S . [Erratum in: Chest. 2012; 141: 1129]
• 47 Moores TS, Beaven A, Cattell AE, Baker C, Roberts PJ. Preoperative warfarin reversal for early hip fracture surgery. J Orthop Surg (Hong Kong) 2015; 23 (01) 33-36
• 48 Beyer-Westendorf J, Gelbricht V, Förster K. , et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35 (28) 1888-1896